Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

Monday, September 23, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. has announced the launch of the Cortera Posterior Fixation System. This new product is designed to streamline thoracolumbar fixation surgeries, enhancing the company's offerings in spinal disorder treatment. The launch reflects Xtant Medical's commitment to innovation in medical technology.
Price reaction · baseline $0.7025 (2024-09-20 close) · hit pre-market · clean, no other XTNT news in the window
day 0 close · peak
+5.3%
day 1
-3.9%
day 3
-3.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a new product enhances the company's portfolio.
  • Cortera system aims to improve thoracolumbar fixation surgeries.
  • Xtant Medical is positioned as a leader in spinal disorder treatment.

Full Press Release Details

BELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leading global medical technology company focused on the treatment of spinal disorders, is excited to announce the launch of the Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries.

Frequently Asked Questions

What is the Cortera Posterior Fixation System?

The Cortera Posterior Fixation System is a new product designed to streamline thoracolumbar fixation surgeries.

Who launched the Cortera system?

Xtant Medical Holdings, Inc. launched the Cortera Posterior Fixation System.

What is the focus of Xtant Medical?

Xtant Medical focuses on the treatment of spinal disorders.

When was the Cortera system launched?

The Cortera Posterior Fixation System was launched on September 23, 2024.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical Cortera spinal disorders thoracolumbar fixation medical technology
Last updated: Sep 23, 2024

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk